Abstract
BACKGROUND: Mavacamten, a small molecule that inhibits cardiac myosin, has shown promise in reducing symptoms and improving cardiac function in patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction. However, data regarding the use of mavacamten in patients with mid-cavitary obstruction (MCO) are limited. CASE SUMMARY: This case report describes the therapeutic success in managing a 56-year-old man presenting with symptomatic MCO, a variant of HCM, through the combined administration of metoprolol and mavacamten. DISCUSSION: Despite the primary evidence for the efficacy of mavacamten being derived from patients with LVOT obstruction, this case demonstrates significant symptomatic improvement and reduced obstruction after treatment with mavacamten. TAKE-HOME MESSAGE: Mavacamten may be effective beyond its primary indication for LVOT obstruction in HCM, highlighting a potential new avenue for the treatment of MCO.